IP Library Granted Patent US 7,399,790
Granted Patent B2
US 7,399,790 · App. 09/795,279 · Granted Jul 15, 2008

Virucidal compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,399,790
App. No.
09/795,279
Granted
Jul 15, 2008
Kind
B2
Abstract

A method of inactivating enveloped virus comprises contacting said virus with a virucidally effective amount of a composition comprising a C1 to C3 monohydroxy alcohol or a C3 to C4 diol and a sufficient amount of an acid to adjust the pH of the composition to below 4.6. Topical administration of the composition is preferred and is effective in treating lesions associated with herpes infections. Pharmaceutical compositions for use in the present method are provided.

Claims (19)

1. A topical composition for inactivating an enveloped virus at a site of infection, said composition consisting of:

(i) an alcohol selected from the group consisting of 2,3-butanediol, 1,2-butanediol, 1,3-butanediol, and 1,4-butanediol;

(ii) a sufficient amount of an organic acid to adjust the pH of the composition to between 2.45 and 4.5; and

(iii) a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein said organic acid is selected from the group consisting of glycolic acid, lactic acid, succinic acid malic acid, citric acid, and acetic acid.

3. The composition of claim 1 , wherein the pH of said composition is 2.45.

4. The composition of claim 1 , wherein the concentration of said alcohol is between about 0.2% and 12.5% by volume.

5. A topical composition for inactivating an enveloped virus, said composition consisting of:

(i) an alcohol having a concentration of 0.2 to 13.0% by volume in water;

(ii) a sufficient amount of an acid to adjust the pH of the composition to between 2.45 and 4.6; and

(iii) a pharmaceutically acceptable carrier, wherein said alcohol is selected from the group consisting of methanol, 1-propanol, 2-propanol, 2,3-butanediol, 1,2-butanediol, 1,3-butanediol, and 1,4-butanediol.

6. A topical composition for inactivating an enveloped virus, said composition consisting of:

(i) a C2-C4 diol having a concentration of 0.2 to 13.0% by volume in water;

(ii) a sufficient amount of an acid to adjust the pH of the composition to between 2.45 and 4.6; and

(iii) a pharmaceutically acceptable carrier, wherein said acid is selected from the group consisting of glycolic acid, lactic acid, succinic acid, malic acid, citric acid, acetic acid, and hydrochloric acid.

7. A topical composition for inactivating a virus selected from the group consisting of herpes simplex 1 virus, herpes simplex 2 virus, and Varicella-zoster virus, said composition consisting of:

(i) an alcohol having a concentration of 0.2 to 13.0%, by volume in water, said alcohol selected from the group consisting of methanol, 1-propanol, 2-propanol, 2,3-butanediol, 1,2-butanediol, 1,3-butanediol, and 1,4-butanediol;

(ii) a sufficient amount of an acid to adjust the pH of the composition to between 2.45 and 4.6, wherein said acid is selected from the group consisting of glycolic acid, lactic acid, succinic acid, malic acid, citric acid, acetic acid, and hydrochloric acid; and

(iii) a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2012
From: LIFE FORCE TECHNOLOGIES, LLC
To: TOPICAL REMEDY, LLC
Reel/Frame 028438/0563 →